Prospective randomized comparative study of antibiotic prophylaxis in urethrocystoscopy and urethrocystography.
BACKGROUND
There has been a great deal of discussion regarding the necessity of the prophylactic use of antibiotics in transurethral procedures. In order to clarify this complicated issue, a randomized prospective study was performed for patients undergoing urethrocystoscopy or urethrocystography.


METHODS
Patients who underwent urethrocystoscopy or urethrocystography and did not have pyuria and bacteriuria were included and divided randomly into 2 groups, either receiving a prophylactic antibiotic or no antibiotic. For antibiotic prophylaxis, 200 mg of sparfloxacin or fleroxacin were administered within a 1-hour period before the urethrocystoscopic or urethrocystographic examination, respectively. Analyses were performed on patients who were seen within 1 month after the examination, using the appearance of pyuria, bacteriuria, or a febrile infection as the endpoint.


RESULTS
Of 47 patients undergoing urethrocystoscopy, 45 were eligible for analysis, and of these, sparfloxacin was administered to 21 patients. Thirty-three of 37 patients undergoing urethrocystography were eligible for analysis with fleroxacin administered to 16 patients. There were no significant differences in the background factors between the 2 groups undergoing either transurethral examination. None of the patients in either group developed pyuria, bacteriuria or a febrile infection after the examination.


CONCLUSIONS
Prophylactic administration of antibiotics is not necessarily essential in urethrocystoscopy or urethrocystography in patients with sterile urine.
Tsugawa
M
M
Department of Urology, Okayama University Medical School, Shikata, Japan.
Monden
K
K
Nasu
Y
Y
Kumon
H
H
Ohmori
H
H
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D003558:Cystoscopy / Q000009:adverse effects*; D005260:Female; D016576:Fleroxacin / Q000627:therapeutic use*; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015363:Quinolones / Q000627:therapeutic use*; D014552:Urinary Tract Infections / Q000209:etiology / Q000517:prevention & control*; D014567:Urography / Q000009:adverse effects*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D016576:Fleroxacin; C061363:sparfloxacin